Japan Syringe Market - Strategic Insights and Forecasts (2026-2031)

The Japan Syringe Market is expected to grow at a CAGR of 4.3%, reaching USD 0.60 billion by 2031 from USD 0.49 billion in 2026, driven by aging demographics and rising injectable drug use.

Japan’s rapidly growing elderly population increases the prevalence of chronic diseases such as diabetes and cancer, sustaining high-volume demand for conventional and specialized syringes used in long-term injectable therapies.

Regulations under the PMD Act and MHLW safety directives promote infection control and needlestick injury prevention, accelerating the shift toward single-use safety syringes and compliant ISO-standard designs.

Widespread adoption of insulin pens and autoinjectors has reduced the need for conventional insulin syringes, although niche demand remains in pediatric care and low-dose clinical settings.

Key drivers include rising chronic disease prevalence, growth in biologics and biosimilars, stricter safety regulations, and increased use of prefilled delivery systems in hospitals and home healthcare.